Depomed Initiates Phase I Trial for DM-1992 Program in PD
 

Depomed Initiates Phase I Trial for DM-1992 Program in Parkinson’s Disease Following Positive Results of Preclinical Studies Sponsored by The Michael J. Fox Foundation

CentralDaily.com / Tuesday, Feb. 17, 2009

MENLO PARK, Calif. — Depomed, Inc. (NASDAQ / DEPO) today announced that it has dosed the first patient in a Phase I trial for its DM-1992 program in Parkinson’s disease based on positive results from preclinical studies sponsored by The Michael J. Fox Foundation for Parkinson’s Research. DM-1992 is an investigative novel gastric retentive extended-release dosage form of Levodopa/Carbidopa, a marketed therapy used in the treatment of Parkinson’s disease.

Click above to find the source